# A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

> **NCT05877924** · PHASE1 · RECRUITING · sponsor: **NovaRock Biotherapeutics, Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** NBL-020 for Injection

## Key facts

- **NCT ID:** NCT05877924
- **Lead sponsor:** NovaRock Biotherapeutics, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-15
- **Primary completion:** 2025-08
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877924, "A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05877924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*